secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2024-10-25T23:59:59+00:00
Accession:  0001558370-24-013664
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix to present Phase I PRX-115 data in late-breaking poster at ACR Convergence 2024
--------------------------------------------------------------------------------

- PRX-115 is a recombinant PEGylated uricase for uncontrolled gout treatment.
- Data from Phase I trial will be presented at ACR Convergence 2024 (Nov 14-19, Washington, D.C.).
- Poster session: Monday Nov 18, 10:30 AM-12:30 PM EST; abstract number L05.
- Abstract available on ACR abstracts website; poster to be posted on Protalix website.
- No clinical results disclosed; presentation details only.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837024013664/0001558370-24-013664-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837024013664/plx-20241025x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-013664

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer